Obesity in subjects with heart failure was associated with 63% lower NT-proBNP plasma levels compared to non-obese subjects (p < 0.01), irrespective of ischaemic or dilated aetiology.
Observational
Does obesity lower NT-proBNP plasma levels in subjects with heart failure?
Obesity is associated with significantly lower NT-proBNP plasma levels in heart failure patients, irrespective of ischemic or dilated etiology, which may impact the diagnostic utility of this biomarker in obese individuals.
Effect estimate: 63% lower
p-value: p=< 0.01
N-terminal pro-brain natriuretic peptide (NT-proBNP) may be useful in the diagnosis of heart failure and ventricular dysfunction. Obesity is an independent cardiovascular risk factor. The purpose of this study was to measure NT-proBNP plasma levels in obese and non-obese subjects with heart failure and to compare levels in subjects with ischaemic and dilated aetiology. In this study, obese subjects had 63% lower NT-proBNP plasma levels than non-obese subjects (p < 0.01). In multivariate analysis, BMI was inversely associated with NT-proBNP plasma levels (p < 0.05) and a 17% decrease in natriuretic peptide levels was attributed to obesity (p < 0.036). When we analyzed data according to the aetiology of heart failure, we found that both groups (ischaemic and dilated) had a 65% decrease in NT-proBNP plasma levels in obese subjects compared to non-obese subjects.
Rivera et al. (Sat,) conducted a observational in Heart failure. Obesity vs. Non-obese subjects was evaluated on NT-proBNP plasma levels (63% lower, p=< 0.01). Obesity in subjects with heart failure was associated with 63% lower NT-proBNP plasma levels compared to non-obese subjects (p < 0.01), irrespective of ischaemic or dilated aetiology.